UPDATE: Phase 1 Trial of Penetrium Shows Early PSA Declines and Metastatic Lesion Shrinkage in Resistant Prostate Cancer

New clinical observations reported in November 2026, suggest that Penetrium (CP-PCA07), an experimental niclosamide-based treatment, may help restore sensitivity to androgen receptor pathway inhibitors in men with metastatic castration-resistant prostate cancer (mCRPC). The findings represent the first reported clinical signals of activity following earlier preclinical research into Penetrium’s ability to overcome treatment resistance.

Penetrium is being developed to address a proposed mechanism called pseudo-resistance, in which changes in the tumor microenvironment, particularly cancer-associated fibroblasts (CAFs) and the extracellular matrix (ECM), create barriers that may limit the penetration and effectiveness of anticancer drugs. Rather than directly attacking cancer cells, Penetrium aims to modify these barriers and improve the activity of existing treatments.

The first patient, whose disease had developed resistance to abiraterone, received Penetrium at 600 mg daily in combination with enzalutamide during a Phase 1 trial at Seoul National University Hospital. Over 12 weeks, investigators observed consecutive PSA declines and a reduction in the size of metastatic lesions on CT imaging. Following completion of the initial treatment period, South Korea’s Ministry of Food and Drug Safety authorized an additional six months of treatment for this individual patient.

A second patient had previously discontinued enzalutamide because of resistance and subsequently experienced approximately ten months of rising PSA. After restarting enzalutamide alongside Penetrium at the same daily dose, PSA declined during both the first and second weeks of treatment.

These observations are particularly interesting because they raise the possibility that resistance to androgen receptor inhibitors may sometimes be influenced by reversible characteristics of the tumor microenvironment, rather than exclusively by permanent changes within cancer cells.

However, the findings currently involve only two patients, and the reported PSA declines have not been accompanied by detailed numerical results or independently assessed response data. The findings therefore represent early clinical observations rather than proof that the proposed pseudo-resistance mechanism has been reversed.

The ongoing Phase 1 program will help investigators further characterize Penetrium’s safety and activity alongside established prostate cancer treatments. Separately, the FDA has permitted a Phase 2a study in patients with relapsed or refractory advanced solid tumors.

Source. (it’s in Korean)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply